Tag Archives | AstraZeneca

Silent Killer: Chronic Kidney Disease in the Middle East

By Viraj Rajadhyaksha (pictured), AstraZeneca Area Medical Director, Middle East and Africa. Exposing the Silent Killer: Addressing chronic kidney disease in the Middle East There is a silent killer in our midst. It affects 850 million people worldwide and is a leading cause of death globally.[1] Despite its deadly profile and rising prevalence in this […]

Iraqi Kurdistan sticks with AstraZeneca Vaccine

By Adam Lucente for Al Monitor. Any opinions expressed are those of the author(s), and do not necessarily reflect the views of Iraq Business News. Iraq's Kurdistan region sticks with AstraZeneca vaccine, reports no issues Kurdish authorities say they will continue administering the vaccine following the European Union's conclusion that blood clots should be listed […]

Iraq receives First Delivery of Vaccines through COVAX Facility

Iraq receives the first delivery of COVID-19 vaccines through the COVAX Facility Amid a global shortage of COVID-19 vaccines, Iraq has finally received 336 000 doses of AstraZeneca COVID-19 vaccine through the COVAX Facility, a partnership co-led by Coalition for Epidemic Preparedness Innovations (CEPI), Gavi - The Vaccine Alliance and the World Health Organization (WHO), […]

Iraq discusses sourcing Covid Vaccine with AstraZeneca

By John Lee. The Ambassador of Republic of Iraq in London, Mr. Muhammad Jaafar Al-Sadr, chaired a meeting with representatives of the British pharmaceutical group, AstraZeneca, which is a leading company in Coronavirus vaccine in cooperation with the University of Oxford in Britain, through video conference. The meeting discussed the possibility of Iraq obtaining adequate […]

AstraZeneca Investigated for Alleged Corruption in Iraq

By John Lee. UK-bassed pharmaceutical company AstraZeneca has said it is the subject of an anti-corruption investigation in the US relating to its activities in Iraq In its latest quarterly filing with the Securities and Exchange Commission (SEC), the company said: "As previously disclosed, in the US, in October 2017, AstraZeneca and certain other pharmaceutical and/or medical device […]